Literature DB >> 17163166

Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models.

Linda Holmquist1, Tobias Löfstedt, Sven Påhlman.   

Abstract

The tumor oxygenation status associates with aggressive behavior. Oxygen shortage, hypoxia, is a major driving force behind tumor vascularization, and hypoxia enhances mutational rate, metastatic spread, and resistance to radiation and chemotherapy. We recently discovered that hypoxia promotes dedifferentiation of neuroblastoma and breast carcinoma cells and development of stem cell-like features. In both these tumor forms there is a correlation between low differentiation stage and poor outcome, and we conclude that the dedifferentiating effect of lowered oxygen adds to the aggressive phenotype induced by hypoxia. With neuroblastoma and breast carcinoma as human tumor model systems, we have addressed questions related to hypoxia-induced molecular mechanisms governing malignant behavior of tumor cells, with emphasis on differentiation and growth control. By global gene expression analyses we are currently screening for gene products exclusively expressed or modified in hypoxic cells with the aim to use them as targets for treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17163166     DOI: 10.1007/978-1-4020-5133-3_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  14 in total

1.  Shutdown of achaete-scute homolog-1 expression by heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1 in hypoxia.

Authors:  Mumtaz Kasim; Edgar Benko; Aline Winkelmann; Ralf Mrowka; Jonas J Staudacher; Pontus B Persson; Holger Scholz; Jochen C Meier; Michael Fähling
Journal:  J Biol Chem       Date:  2014-08-14       Impact factor: 5.157

2.  Oxidative status in neuroblastoma: a source of stress?

Authors:  Nathan M Novotny; Jay L Grosfeld; Katharyn E Turner; Frederick J Rescorla; Xinzhu Pu; James E Klaunig; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  J Pediatr Surg       Date:  2008-02       Impact factor: 2.545

3.  Normobaric hyperoxia inhibits the progression of lung cancer by inducing apoptosis.

Authors:  Sei Won Kim; In Kyoung Kim; Jick Hwan Ha; Chang Dong Yeo; Hyeon Hui Kang; Jin Woo Kim; Sang Haak Lee
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

Review 4.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

Review 5.  Hyperbaric oxygen therapy and cancer--a review.

Authors:  Ingrid Moen; Linda E B Stuhr
Journal:  Target Oncol       Date:  2012-10-02       Impact factor: 4.493

6.  PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1α expression in MCF-7 breast cancer cells.

Authors:  Jun Du; Rui Xu; Zhenzhen Hu; Yinhui Tian; Yichao Zhu; Luo Gu; Lei Zhou
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

7.  Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells.

Authors:  Vasantha Kumar Bhaskara; Indra Mohanam; Jasti S Rao; Sanjeeva Mohanam
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

8.  Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2.

Authors:  Claire E Lewis; Russell Hughes
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  Neuritogenic and neuroprotective effects of polar steroids from the Far East starfishes Patiria pectinifera and Distolasterias nipon.

Authors:  Natalia V Palyanova; Tatyana M Pankova; Marina V Starostina; Alla A Kicha; Natalia V Ivanchina; Valentin A Stonik
Journal:  Mar Drugs       Date:  2013-05-03       Impact factor: 5.118

Review 10.  Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes.

Authors:  Guoliang Qing; M Celeste Simon
Journal:  Curr Opin Genet Dev       Date:  2009-01-21       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.